gelteq.com (GELS) Long-Term Liabilities to Equity

Gelteq Limited results depend on regulatory drug approvals rather than GDP. The long-term debt-to-equity ratio confirms the stability of this trend, where the 0.00 mark serves as a key metric. The business relies on a protected nutrient delivery system via gel capsules, aiming to license its patents to global behemoths without pursuing corporate mergers.

This indicator determines the proportion of liabilities with a maturity exceeding one year relative to equity. The calculation focuses on long-term leverage, where low values minimize bankruptcy risks, while their absence may signal an underutilization of borrowed capital. By analyzing the long-term debt-to-equity structure, an investor assesses financial stability. For Gelteq Limited (GELS), such a debt management strategy complements the diversification of their gel platforms, reducing the overall risks of the biotech pipeline.